Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

CPI is expected to rise 0.23%–0.25%, with inflationary pressures persisting. Check out market impacts, top sector picks, and ...